
Dec 15 (Reuters) - ALZPATH INC:
ALZPATH AND SIEMENS HEALTHINEERS SHLG.DE SIGN LICENSING AGREEMENT TO ADVANCE GLOBAL ACCESS TO BLOOD-BASED ALZHEIMER'S DISEASE DIAGNOSTIC TESTING
LICENSING FOR USE OF ITS PROPRIETARY PTAU217 ANTIBODY IN DEVELOPMENT OF A PTAU217 ASSAY IN EXPANDING MENU OF SIEMENS HEALTHINEERS IN VITRO DIAGNOSTIC (IVD) TESTS FOR ALZHEIMER'S DISEASE
Further company coverage: []